Accelerated Infliximab Induction for Severe Lower Gastrointestinal Bleeding in a Young Patient with Crohn's Disease: A Case Report

被引:1
|
作者
Zeng, Jing [1 ]
Shen, Feng [1 ]
Fan, Jian-Gao [1 ]
Ge, Wen-Song [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Xinhua Hosp, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
Crohn's disease; Severe lower gastrointestinal bleeding; Steroid hormone; Accelerated infliximab induction; Case report; HEMORRHAGE;
D O I
10.12998/wjcc.v10.i2.733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Severe lower gastrointestinal bleeding (SLGIB) is a rare complication of Crohn's disease (CD). The treatment of these patients is a clinical challenge. Monoclonal anti-TNF alpha antibody (IFX) can induce relatively fast mucosal healing. It has been reported for the treatment of SLGIB, but there are few reports on accelerated IFX induction in CD patients with SLGIB. CASE SUMMARY A 16-year-old boy with a history of recurrent oral ulcers for nearly 1 year presented to the Gastroenterology Department of our hospital complaining of recurrent periumbilical pain for more than 1 mo and having bloody stool 4 times within 2 wk. Colonoscopy showed multiple areas of inflammation of the colon and a sigmoid colon ulcer with active bleeding. Hemostasis was immediately performed under endoscopy. The physical examination of the patient showed scattered small ulcers in the lower lip of the mouth and small cracks in the perianal area. Combined with his medical history, physical examination, laboratory examinations with high C-reactive protein (CRP), platelet count (PLT), erythrocyte sedimentation rate (ESR) and fecal calprotectin levels, imaging examinations and pathology, a diagnosis of CD was taken into consideration. According to the pediatric CD activity index 47.5, methylprednisolone (40 mg QD) was given intravenously. The abdominal pain disappeared, and CRP, PLT, and ESR levels decreased significantly after the treatment. Unfortunately, he had a large amount of bloody stool again after 1 wk of methylprednisolone treatment, and his hemoglobin level decreased quickly. Although infliximab (IFX) (5 mg/kg) was given as a combination therapy regimen, he still had bloody stool with his hemoglobin level decreasing from 112 g/L to 80 g/L in a short time, so-called SLGIB. With informed consent, accelerated IFX (5 mg/kg) induction was given 7 days after initial presentation. The bleeding then stopped. Eight weeks after the treatment, repeat colonoscopy showed mucosal healing; thus far, no recurrent bleeding has occurred, and the patient is symptom-free. CONCLUSION This case highlights the importance of accelerated IFX induction in SLGIB secondary to CD, especially after steroid hormone treatment.
引用
收藏
页码:733 / 740
页数:8
相关论文
共 50 条
  • [31] Arterial embolization in the treatment of massive lower gastrointestinal bleeding in patients with Crohn's disease
    Martin, Veronica
    Rubi, Alicia R.
    Chaparro, Maria
    Jusue, Vanesa
    Friera, Alfonsa
    Gisbert, Javier P.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (09): : 574 - 576
  • [32] Case report: Gastrointestinal tuberculosis simulating Crohn's disease
    Kaushik, SP
    Bassett, ML
    McDonald, C
    Lin, BPC
    Bokey, E
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1996, 11 (06) : 532 - 534
  • [33] Utility of infliximab therapy in severe enterorrhagia associated with Crohn's disease. Report of three cases
    Alcalde Vargas, Alfonso
    Herrera Justiniano, Jose Manuel
    Leo Carnerero, Eduardo
    Trigo Salado, Claudio
    Gutierrez Domingo, Ignacio
    Marquez Galan, Jose Luis
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2011, 34 (01): : 24 - 28
  • [34] Gastrointestinal involvement in a patient with familial Mediterranean fever mimicking Crohn’s disease: a case report
    Yoshihiro Yokoyama
    Tsukasa Yamakawa
    Tadashi Ichimiya
    Tomoe Kazama
    Daisuke Hirayama
    Kohei Wagatsuma
    Hiroshi Nakase
    Clinical Journal of Gastroenterology, 2021, 14 : 1103 - 1107
  • [35] Treatment of severe esophageal Crohn's disease with infliximab
    Heller, T
    James, SP
    Drachenberg, C
    Hernandez, C
    Darwin, PE
    INFLAMMATORY BOWEL DISEASES, 1999, 5 (04) : 279 - 282
  • [36] Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report
    Xiao, Lin
    Sun, Lie
    Zhao, Kang
    Pan, Yi-Sheng
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (04) : 305 - 311
  • [37] A case report of gastrointestinal histoplasmosis in a patient treated with infliximab
    Berta Oliveras
    Marc Albert
    Carme López
    Esther Fort
    Laia Peries
    Laia Gutiérrez
    David Busquets
    Hugo Uchima
    Xavier Aldeguer
    Virginia Piñol
    Clinical Journal of Gastroenterology, 2021, 14 : 690 - 692
  • [38] Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature
    Grillo, Thais Gagno
    Almeida, Luciana Rocha
    Beraldo, Rodrigo Fedatto
    Marcondes, Mariana Barros
    Rios Queiroz, Diego Aparecido
    da Silva, Daniel Luiz
    Quera, Rodrigo
    Baima, Julio Pinheiro
    Saad-Hossne, Rogerio
    Sassaki, Ligia Yukie
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (33) : 10382 - 10391
  • [39] A case report of gastrointestinal histoplasmosis in a patient treated with infliximab
    Oliveras, Berta
    Albert, Marc
    Lopez, Carme
    Fort, Esther
    Peries, Laia
    Gutierrez, Laia
    Busquets, David
    Uchima, Hugo
    Aldeguer, Xavier
    Pinol, Virginia
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (02) : 690 - 692
  • [40] Mucormycosis in a Crohn's Disease Patient Treated with Infliximab
    Wall, Geoffrey C.
    Leman, Bernard I.
    DIGESTION, 2009, 80 (03) : 182 - 184